Changes in the rcbf images of patients with alzheimer’s disease receiving donepezil therapy

Nuclear Medicine Communications

Volumn 21, Issue 1, 2000, Pages 37-41

  Staff, R T ^a   Gemmell, H G ^a   Shanks, M F ^a   Murray, A D ^a   Venneri, A ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; DONEPEZIL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CIRCULATION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; IMAGE PROCESSING; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033629055     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200001000-00007     Document Type: Review

References (14)

1. Davis P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976; 2: 1403.
2. Giacobini E, Becker R. Present progress and future development in the therapy for Alzheimer’s disease. in Iqbal K, Wisniewski HM, Winblad B, eds. Alzheimer’s disease and related disorders. New York: Alan R. Liss, 1989: 1121-1154.
3. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of Donepezil in patients with Alzheimer’s disease. Neurology 1998;: 136-145.
4. Warren S, Hier DB, Pavel D. Visual form of Alzheimer’s disease and its response to anticholinesterase therapy. J Neuroimaging 1998; 8: 249-252.
5. Brown DR, Hunter R, Wyper DJ et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer’s disease: A SPECT blood flow study. J Psychiat Res 1996; 30: 109-261.
6. McKhann G, Drachman D, Folstein M, Katzman R, Prince D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Workgroup, under the auspices of the Department of Health and Human Services Taskforce on Alzheimer’s Disease. Neurology 1984; 34: 939-994.
7. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25: 638-643.
8. Talairach J, Tournoux P, eds. Co-planar stereotatic atlas of the human brain. Stuttgart: Thieme, 1988.
9. Friston KJ, Ashburner J, Firth CD, Poline JB, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Hum Brain Mapping 1995; 2: 165-189.
10. Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: Beyond PET and fMRI activation studies. Eur J Nucl Med 1998; 25: 663-667.
11. Staff RT, Shanks MF, Macintosh L, Pestell SJ, Gemmell HG, Venneri A. Delusions in Alzheimer’s disease: SPET evidence of right hemispherical dysfunction. Cortex (in press).
12. Pickut BA, Dierckx RA, Dobbeleir A et al. Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiat Res Neuroimag 1999; 90: 103-113.
13. Scremin OU, Li MG, Scremin AM, Jenden DJ. Cholinesterase inhibition improves blood flow in ischemic cerebral cortex. Brain Res Bull 1997; 42: 59-70.
14. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and apoptosis E4 in medial temporal lobe. Int Psychogeriatrics 1998; 10: 271-302.